{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T10:54:38Z","timestamp":1792580078353,"version":"4.5.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,19]]},"DOI":"10.7759\/cureus.52564","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T14:58:41Z","timestamp":1705676321000},"source":"Crossref","is-referenced-by-count":15,"title":["Tendency of Semaglutide to Induce Gastroparesis: A Case Report"],"prefix":"10.7759","author":[{"given":"Ahtshamullah","family":"Chaudhry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buluku","family":"Gabriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawad","family":"Noor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saima","family":"Jawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suryanarayana R","family":"Challa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"What To Know About Gastroparesis. Lawsuit Claims Ozempic And Mounjaro Causes The Severe Stomach Disorder. (2023). Accessed: November 7, 2023: https:\/\/www.forbes.com\/sites\/ariannajohnson\/2023\/08\/14\/what-to-know-about-gastroparesis-lawsuit-claims-ozempic-and-mo...."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-018-0454-9","article-title":"Diabetic gastroparesis: principles and current trends in management","volume":"9","author":"Krishnasamy S","year":"2018","unstructured":"Krishnasamy S, Abell TL. Diabetic gastroparesis: principles and current trends in management. Diabetes Ther. 2018, 9:1-42. 10.1007\/s13300-018-0454-9","journal-title":"Diabetes Ther"},{"key":"ref3","unstructured":"Clinical Review Report. Semaglutide (Ozempic): (Novo Nordisk Canada Inc.): Indication: For the treatment of adult patients with type 2 diabetes mellitus to improve glycemic control, in combination with metformin (second-line treatment), and in combination with metformin and sulfonylurea (third-line treatment) [Internet]. (2019). Accessed: November 7, 2023: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK544016\/."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/23247096211051919","article-title":"Medication-induced gastroparesis: a case report","volume":"9","author":"Kalas MA","year":"2021","unstructured":"Kalas MA, Galura GM, McCallum RW. Medication-induced gastroparesis: a case report. J Investig Med High Impact Case Rep. 2021, 9:23247096211051919. 10.1177\/23247096211051919","journal-title":"J Investig Med High Impact Case Rep"},{"key":"ref5","article-title":"Management of gastroparesis","volume":"17","author":"Zheng T","year":"2021","unstructured":"Zheng T, Camilleri M. Management of gastroparesis. Gastroenterol Hepatol (N Y). 2021, 17:515-25.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-021-09699-1","article-title":"Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes","volume":"23","author":"Mahapatra MK","year":"2022","unstructured":"Mahapatra MK, Karuppasamy M, Sahoo BM. Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Rev Endocr Metab Disord. 2022, 23:521-39. 10.1007\/s11154-021-09699-1","journal-title":"Rev Endocr Metab Disord"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2337\/db10-1790","article-title":"Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual \u03b2-cell function","volume":"60","author":"Kielgast U","year":"2011","unstructured":"Kielgast U, Holst JJ, Madsbad S. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual \u03b2-cell function. Diabetes. 2011, 60:1599-607. 10.2337\/db10-1790","journal-title":"Diabetes"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318712","article-title":"Gastroparesis: a turning point in understanding and treatment","volume":"68","author":"Grover M","year":"2019","unstructured":"Grover M, Farrugia G, Stanghellini V. Gastroparesis: a turning point in understanding and treatment. Gut. 2019, 68:2238-50. 10.1136\/gutjnl-2019-318712","journal-title":"Gut"},{"key":"ref9","article-title":"","year":"2019","unstructured":"Encyclopedia of Gastroenterology. Academic Press, Cambridge, MA; 2019."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2967\/jnmt.117.227892","article-title":"Gastric emptying scintigraphy","volume":"47","author":"Farrell MB","year":"2019","unstructured":"Farrell MB. Gastric emptying scintigraphy. J Nucl Med Technol. 2019, 47:111-9. 10.2967\/jnmt.117.227892","journal-title":"J Nucl Med Technol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/jim-2022-002480","article-title":"Frequency of GLP-1 receptor agonists use in diabetic patients diagnosed with delayed gastric emptying and their demographic profile","volume":"71","author":"Kalas MA","year":"2023","unstructured":"Kalas MA, Dang TQ, Galura G, Alvarado L, Dwivedi AK, Deoker A, McCallum R. Frequency of GLP-1 receptor agonists use in diabetic patients diagnosed with delayed gastric emptying and their demographic profile. J Investig Med. 2023, 71:11-6. 10.1136\/jim-2022-002480","journal-title":"J Investig Med"},{"key":"ref12","article-title":"Treatment challenges in the management of gastroparesis-related GERD","volume":"5","author":"Fass R","year":"2009","unstructured":"Fass R, McCallum RW, Parkman HP. Treatment challenges in the management of gastroparesis-related GERD. Gastroenterol Hepatol (N Y). 2009, 5:4-16.","journal-title":"Gastroenterol Hepatol (N Y)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/212775-tendency-of-semaglutide-to-induce-gastroparesis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:17:00Z","timestamp":1707509820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/212775-tendency-of-semaglutide-to-induce-gastroparesis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,19]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.52564","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,19]]}}}